Recent Updates
Recently added Catalysts

APD791

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Jul 4, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials2
Total Enrollment140
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00619931A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy VolunteersPHASE1 COMPLETED 50Jan 1, 2008Jun 1, 2008Jul 4, 2022 -
NCT00529646Single-Dose Safety Study of APD791 in Healthy VolunteersPHASE1 COMPLETED 90Jul 30, 2007 -Dec 29, 2008 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
APD791DRUGAPD791 or matching placebo in escalating doses
Unlock Study Design Details